NXL היקף נכסי החברה nexalin.com

Nexalin Technology, Inc. (NXL) is integrating neurostimulation devices into medical centers, ensuring steady sales of consumables by leveraging professional physician loyalty. The global rise in PTSD driven by conflicts is stimulating demand for such technologies, although sanctions may hinder exports. The stock price trend reflects total assets at 4.78, as the business prepares to launch high-tech non-invasive brain stimulation systems.

For Nexalin Technology, Inc. (NXL), whose capital is based on patents in the field of non-invasive brain stimulation, total assets reflect the scale of resources available for scaling clinical advantages. A reverse calculation via ROA allows for the daily tracking of changes in controlled resources, revealing the balance sheet's actual resilience to market shocks and helping investors determine the company's degree of overvaluation relative to its tangible asset base.